25985-08-4

Upstream product

• 17356-08-0 thiourea 
• 824-94-2 p-methoxybenzyl chloride 
• 105-13-5 4-Methoxybenzyl alcohol 
• 2746-25-0 p-Methoxybenzyl bromide 

Downstream Products

• 108932-05-4 4-(2,3-dichlorophenyl)-1,4-dihydro-2-[[(4-methoxyphenyl)methyl]thio]-6-methyl-5-pyrimidinecarboxylic acid, ethyl ester 
• 123486-03-3 1,4-dihydro-2-<<(4-methoxyphenyl)methyl>thio>-6-methyl-4-<2-(trifluoromethyl)phenyl>-5-pyrimidinecarboxylic acid ethyl ester monohydrochloride 
• 108931-96-0 1,4-Dihydro-2-[[(4-methoxyphenyl)methyl]-thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid,ethyl ester 
• 142929-91-7 2-(4-Methoxy-benzylsulfanyl)-6-methyl-4-(2-trifluoromethyl-phenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid 2-(benzyl-methyl-amino)-ethyl ester 
• 108932-12-3 1,4-dihydro-2-[[(4-methoxyphenyl)methyl]thio]-6-methyl-4-(3-nitrophenyl)-5-pyrimidinecarboxylic acid, 2-[methyl(phenylmethyl)amino]ethyl ester 
• 142946-43-8 2-(4-Methoxy-benzylsulfanyl)-6-methyl-4-(2-trifluoromethyl-phenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid 1-benzyl-piperidin-4-yl ester 
• 110661-59-1 (p-methoxyphenyl)methanesulfonyl chloride 
• 84747-20-6 4-amino-2-(4-methoxybenzyl)thio-1,3,5-triazine 
• 142929-94-0 2-(4-Methoxy-benzylsulfanyl)-4-methyl-6-(3-nitro-phenyl)-6H-pyrimidine-1,5-dicarboxylic acid 5-[2-(benzyl-methyl-amino)-ethyl] ester 1-ethyl ester 
• 142929-96-2 2-(4-Methoxy-benzylsulfanyl)-4-methyl-1-propyl-6-(2-trifluoromethyl-phenyl)-1,6-dihydro-pyrimidine-5-carboxylic acid 1-benzyl-piperidin-4-yl ester 
• 108932-31-6 1,6-Dihydro-2-[[(4-methoxyphenyl)methyl]thio] 4-methyl-6-(3-nitrophenyl)-1-(1-oxopropyl)-5 pyrimidinecarboxylic acid, methyl ester 
• 123485-94-9 1,4-dihydro-2-<<(4-methoxyphenyl)methyl>thio>-6-methyl-4-(3-nitrophenyl)-1-propyl-5-pyrimidinecarboxylic acid ethyl ester 
• 123486-04-4 1,4-dihydro-2-<<(4-methoxyphenyl)methyl>thio>-6-methyl-4-<2-(trifluoromethyl)phenyl>-1-propyl-5-pyrimidinecarboxylic acid ethyl ester 
• 123486-08-8 1,6-dihydro-2-<<(4-methoxyphenyl)methyl>thio>-4-methyl-6-(3-nitrophenyl)-1-propyl-5-pyrimidinecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Dihydropyrimidinones and -thiones with improved activity against human polyomavirus family members

Human polyomaviruses are generally latent but can be reactivated in patients whose immune systems are suppressed. Unfortunately, current therapeutics for diseases associated with polyomaviruses are non-specific, have undefined mechanisms of action, or exa

Synthesis of difluoromethyl and deuterium-labeled difluoromethyl thioethers from aliphatic electrophiles

A one-pot difluoromethylthiolation of alkyl electrophiles with thiourea and diethyl bromodifluoromethylphosphonate is described. The transition-metal-free approach, readily available reagents, and mild conditions provide a practical way for the synthesis of difluoromethyl thioethers. By changing the "H" source to the most commonly used "D" sources CD3OD and D2O, this strategy enables efficient synthesis of SCF2D-substituted molecules in good yields with high levels of D incorporation.

Novel and highly efficient synthesis of 3-(alkyl/benzylthio)-9b-hydroxy-1H-imidazo[5,1-a]isoindole-1,5(9bH)-dione derivatives

The oxidation of 3a,8a-dihydroxy-2-(alkyl/benzylthio)indeno[1,2-d]imidazol-8(3H)-ones to give the corresponding 3-(alkyl/benzylthio)-9b-hydroxy-1H-imidazo[5,1-a]isoindole-1,5(9bH)-dione derivatives in good to excellent yields at room temperature using two oxidants, periodic acid in aqueous ethanol and lead(IV) acetate in acetic acid, has been reported.

S-Benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase

S-Benzylisothiourea 3a was discovered by its ability to inhibit indoleamine-2,3-dioxygenase (IDO) in our screening program. Subsequent optimization of the initial hit 3a lead to the identification of sub-μM inhibitors 3r and 10h, both of which suppressed kynurenine production in A431 cells. Synthesis and structure-activity relationship of S-benzylisothiourea analogues as small-molecule inhibitors of IDO are described.

INHIBITION OF CELL PROLIFERATION

The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.

SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

A method for the introduction of reporter groups into moenomycin A, based on thiouronium salt chemistry

p-Alkoxy-substituted cinnamylthiouronium salts 7, 13, 21a, and 21b reacted selectively with the 2-acylamino-1,3-cyclopentanedione unit A of moenomycin A (1) to give the corresponding 2-alkylated products 14a, 14b, 22a, and 22b. These products, depending on the pH of the solution, were either stable under the reaction conditions or they underwent retro-Claisen-type reactions. The method can be used for the attachment of reporter groups to moenomycin A for the synthesis of, for example, 25. Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002).

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Creceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Creceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human α1Areceptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the α1Areceptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

5-(HETEROCYCLIC ALKYL)-6-ARYL-DIHYDROPYRIMIDINES

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human α 1C receptors and which have the structure: STR1 wherein A is aryl; R 1, R 2 and R. sub.3 are alkyl or heteroalkyl; R 4 is heterocyclic alkyl; and X is S, O or NR 3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human α 1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.